CryoPort (NASDAQ:CYRX) Now Covered by Analysts at Stephens

Stephens began coverage on shares of CryoPort (NASDAQ:CYRX - Get Free Report) in a research note issued on Tuesday, July 22nd, MarketBeat Ratings reports. The brokerage set an "overweight" rating and a $13.00 price target on the stock. Stephens' price target indicates a potential upside of 71.96% from the company's current price.

Several other research analysts have also recently weighed in on CYRX. Needham & Company LLC restated a "buy" rating and set a $11.00 price target on shares of CryoPort in a report on Thursday, May 8th. BTIG Research cut their target price on CryoPort from $13.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday, July 7th. UBS Group increased their price target on CryoPort from $10.00 to $11.00 and gave the company a "buy" rating in a research report on Tuesday, April 1st. Roth Mkm reissued a "buy" rating and issued a $15.00 price objective on shares of CryoPort in a research report on Tuesday, April 1st. Finally, Guggenheim reissued a "buy" rating and issued a $10.00 price target on shares of CryoPort in a report on Wednesday, April 16th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, CryoPort presently has a consensus rating of "Moderate Buy" and a consensus target price of $11.11.

CryoPort Stock Down 1.2%

Shares of CYRX traded down $0.09 on Tuesday, reaching $7.56. The company's stock had a trading volume of 693,341 shares, compared to its average volume of 390,238. CryoPort has a twelve month low of $4.58 and a twelve month high of $9.66. The stock has a market capitalization of $379.06 million, a PE ratio of -3.23 and a beta of 1.89. The company has a current ratio of 5.56, a quick ratio of 5.24 and a debt-to-equity ratio of 0.51. The firm has a fifty day moving average of $6.94 and a 200-day moving average of $6.58.

CryoPort (NASDAQ:CYRX - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. The company had revenue of $41.04 million for the quarter, compared to analyst estimates of $56.19 million. CryoPort had a negative return on equity of 11.03% and a negative net margin of 50.15%. Equities analysts predict that CryoPort will post -0.99 EPS for the current year.

Insider Transactions at CryoPort

In other news, Director Ramkumar Mandalam sold 40,728 shares of CryoPort stock in a transaction dated Tuesday, July 22nd. The shares were sold at an average price of $7.24, for a total value of $294,870.72. Following the completion of the transaction, the director owned 92,328 shares in the company, valued at $668,454.72. This trade represents a 30.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Edward J. Zecchini sold 51,500 shares of the business's stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $6.84, for a total transaction of $352,260.00. Following the completion of the sale, the insider directly owned 90,411 shares in the company, valued at approximately $618,411.24. This trade represents a 36.29% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 490,447 shares of company stock valued at $3,337,198. 10.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On CryoPort

Hedge funds and other institutional investors have recently bought and sold shares of the business. CWM LLC raised its stake in shares of CryoPort by 56.2% during the 2nd quarter. CWM LLC now owns 17,697 shares of the company's stock valued at $132,000 after purchasing an additional 6,369 shares during the period. Avanza Fonder AB lifted its holdings in shares of CryoPort by 31.4% in the second quarter. Avanza Fonder AB now owns 10,882 shares of the company's stock worth $81,000 after buying an additional 2,601 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of CryoPort by 7.3% in the second quarter. Assenagon Asset Management S.A. now owns 1,090,511 shares of the company's stock worth $8,135,000 after buying an additional 73,949 shares in the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in shares of CryoPort in the second quarter valued at approximately $123,000. Finally, Rhumbline Advisers grew its stake in CryoPort by 23.8% during the first quarter. Rhumbline Advisers now owns 78,320 shares of the company's stock valued at $476,000 after acquiring an additional 15,036 shares in the last quarter. Institutional investors own 92.90% of the company's stock.

About CryoPort

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.